BioSpace News Archive

The reports at TMR Research provide qualitative solutions that break the barriers of doubt or uncertainties when the stakeholders plan to expand their growth reach.

NeuExcell Therapeutics has announced a $10+ million Series Pre-A financing round.

Fact.MR – A Market Research and Competitive Intelligence Provider: A new report by Fact.MR has estimated that combined immune deficiency market will grow at a healthy rate through 2021 and beyond.

XPhyto Therapeutics Corp. with its partner and acquisition target, 3a-diagnostics GmbH, has successfully registered their first biosensor test in oral inflammation with the German authorities.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in September 2021.

Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, announced shipment of the first commercial MERSCOPETM Platforms, marking the successful start of their limited summer release program.

Revelation Biosciences, Inc. and Petra Acquisition, Inc. announced they have entered into a definitive merger agreement for a business combination that will result in Revelation becoming a publicly traded company.

ediciNova, Inc. announced that an abstract regarding MediciNova’s ongoing Phase 2b/3 clinical trial of MN-166 in amyotrophic lateral sclerosis has been accepted for presentation at the 32nd International Symposium on ALS/MND to be held virtually on December 7 - 10, 2021.

Henry Schein, Inc. announced today that the Company will present at two investor conferences in September: Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 1:15 p.m. Eastern time Baird 2021 Virtual Global Healthcare Conference on September 14, 2021, at 12:50 p.m. Eastern Time

IN8bio, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, announced that William Ho, President, Chief Executive Officer and co-founder of IN8bio, will present at the NewYorkBIO Virtual Breakfast Series and the virtual H.C. Wainwright 23rd Annual Global Investment Conference.